An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

Marta Sobas, Pau Montesinos, Blanca Boluda, Teresa Bernal, Edo Vellenga, Josep Nomdedeu, Jose González-Campos, Maria Chillón, Aleksandra Holowiecka, Jordi Esteve, Juan Bergua, José David González-Sanmiguel, Cristina Gil-Cortes, Mar Tormo, Olga Salamero, Felix Manso, Isolda Fernández, Javier de la Serna, María José Moreno, Manuel Pérez-EncinasIsabel Krsnik, Josep Maria Ribera, Lourdes Escoda, Bob Lowenberg, Miguel Angel Sanz

Research output: Contribution to journalArticleResearch

3 Citations (Scopus)

Abstract

© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p =.02) and 5-years cumulative incidence of relapse (33% versus 10%, p =.006), irrespectively of the Sanz score (low-risk 47% versus 5%, p <.001; intermediate 23% versus 7%, p <.001; and high-risk 42% versus 21%, p =.007). In the multivariate analysis, CD56 + (p <.0001), higher relapse-risk score (p =.001), and male gender (p =.05) retained the independent predictive value. CD56+ APL also showed a greater risk of CNS relapse (6% versus 1%, p <.001) and lower 5-year OS (75% versus 83%, p =.003). The AIDA-based LPA2012 trial, with an intensified consolidation schedule for CD56+ APL, will elucidate whether an intensified consolidation schedule could mitigate the relapse rate in this setting.
Original languageEnglish
Pages (from-to)1030-1035
JournalLeukemia and Lymphoma
Volume60
DOIs
Publication statusPublished - 21 Mar 2019

Keywords

  • Acute promyelocytic leukemia
  • ATRA
  • CD56
  • chemotherapy
  • prognostic
  • relapse

Fingerprint

Dive into the research topics of 'An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens'. Together they form a unique fingerprint.

Cite this